Only device-based
oncology with four
FDA approvals.
TTFields is its own category — and prescribed alongside chemotherapy and immunotherapy, not against them.
↓ scroll to read
✦ The bottom line
NovoCure's moat is category-creation. TTFields is currently the only device-based oncology therapy approved by the FDA for solid tumors. Four approved indications — glioblastoma, pancreatic cancer (just approved), NSCLC, and mesothelioma — backed by a fortress of patents and 217 sales-force colleagues worldwide.
↓ the brief below
✦ Teach me
Why being a 'device that adds to drugs' matters
Almost every oncology approval is a new drug that displaces an old drug — meaning each launch is a competition. TTFields is different: it's prescribed with the chemo or immunotherapy, not instead of it. That dramatically reduces the political battle over formularies. Oncologists can add it to the existing regimen; insurance is the bigger question.
Wall Street calls this
Adjunctive therapy
A treatment that complements existing care has lower clinical risk and higher physician acceptance — but its growth still depends on insurance saying yes.
The active footprint · patients on therapy
4,791
patients
4,791 active patients globally as of March 31, 2026 — 4,543 on Optune Gio (brain cancer), 165 on Optune Lua (lung), 83 on Optune Pax (pancreatic).
What expands the moat further is the pipeline of trials — most run in partnership with global oncology platforms like Merck (KEYNOTE-D58) and Roche (Tecentriq combination). Each successful trial adds an indication; each indication is its own reimbursement battle won.
How TTFields became a category
2000
Novocure founded in Haifa, Israel by Dr. Yoram Palti — physicist studying electric fields and cell biology.
2011
FDA approves Optune (first generation) for recurrent glioblastoma.
2015
IPO on Nasdaq; Optune Gio approved for newly diagnosed glioblastoma.
2024
Optune Lua approved for advanced NSCLC; partnership with Zai Lab expands Greater China.
Feb 2026
Optune Pax approved for locally advanced pancreatic cancer — third approved cancer; first new indication in 8 years.
The strategy, in management's words
Our focus remains on bringing Tumor Treating Fields therapy to patients diagnosed with some of the most aggressive forms of cancer, further exploring the use of our therapy to benefit patients in need, and achieving sustainable growth and profitability.
↳ Three things: cancer therapy, expand into more indications, finally make money. The first two are happening; the third is what 2026 will judge.